News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: RuiYi (formerly Anaphore) Signs Up Shanghai's Genor to Develop mAb in China


5/20/2013 9:24:09 AM

by Richard Daverman, PhD

May 18, 2013 -- RuiYi Inc., a San Diego-Shanghai biotech, signed an exclusive license with Genor BioPharma of Shanghai to develop RuiYi’s lead molecule in China; RuiYi also enlisted CMC Biologics to develop a cell line for RYI-008; Vectura, a UK maker of inhaled therapies, established a China respiratory JV with two partners: Tianjin KingYork and Zendex Bio Strategy; SciClone Pharma in-licensed China rights to a heart failure drug from Zensun (Shanghai) Science & Technology; WuXi PharmaTech released positive financial results and candidly discussed the performance of its business units; Amgen, which has not had a major presence in China, is now making good on its promise to use partnerships to establish itself; and BioDuro opened a new CRO laboratory in Shanghai, complementing its existing facility in Beijing. More details…..

Stock Symbols: (LSE: VEC) (NSDQ: SCLN) (NYSE: WX) (NSDQ: AMGN)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES